This announcement is a separate document:
Bellerophon Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Janus Henderson Group plc(12.1%),Janus Henderson Biotech Innovation Master Fund Ltd(10.4%)
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.